Centessa Pharmaceuticals

Helophilia

Biotech

Centessa drops hemophilia B drug following Pfizer’s Hympavzi win

After Pfizer secured approval for Hympavzi, Centessa decided that taking its own contender to market isn't worth the effort.

James Waldron Nov 12, 2024 9:45am

Anaptys picks up rival to Biogen autoimmune asset from Centessa

Nov 28, 2023 6:30am

Liver doctor holding liver

Elevated liver enzymes force Centessa to drop another asset

Aug 10, 2022 9:34am

visual of money going into a piggy bank

Centessa dumps top program after evidence of tolerability issues

Jun 2, 2022 11:25am

blood clot

Centessa hemophilia drug shows reduction of bleeding in phase 2

Sep 9, 2021 9:47am

Financial documents next to blocks that spell IPO

Centessa Pharma eyeing $250M IPO to fund early drug development

May 24, 2021 11:00am